The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
11 2019
Historique:
received: 17 01 2019
revised: 22 05 2019
accepted: 21 06 2019
pubmed: 2 7 2019
medline: 14 4 2020
entrez: 2 7 2019
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of β6 mRNA correlated strongly with significantly poorer survival (n = 491 cases, p = 3.17 × 10

Identifiants

pubmed: 31259422
doi: 10.1002/path.5320
pmc: PMC6852434
doi:

Substances chimiques

Antigens, Neoplasm 0
Antineoplastic Agents, Immunological 0
Integrins 0
integrin alphavbeta6 0
Cre recombinase EC 2.7.7.-
Integrases EC 2.7.7.-
Dual Specificity Phosphatase 6 EC 3.1.3.48
Dusp6 protein, mouse EC 3.1.3.48

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

332-342

Subventions

Organisme : CRUK Core Facilities at Barts Cancer Institute, London
ID : C16420/A18066
Pays : International
Organisme : Pancreatic Cancer UK
ID : FLF2015_04_GLASGOW
Pays : United Kingdom
Organisme : Pancreatic Cancer UK
ID : RIF2015_A06_JAMIESON
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 11650
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Training Fellowship
Pays : International
Organisme : Medical Research Council
ID : G0800825
Pays : United Kingdom

Informations de copyright

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Références

Cancer Cell. 2009 Jun 2;15(6):489-500
pubmed: 19477428
Oncogene. 2013 Sep 12;32(37):4406-16
pubmed: 23108397
J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51
pubmed: 7673344
Curr Opin Genet Dev. 2011 Feb;21(1):93-9
pubmed: 21251810
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Invest Dermatol. 2001 Jul;117(1):67-73
pubmed: 11442751
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Histopathology. 2004 Sep;45(3):226-36
pubmed: 15330800
Cancer Res. 2007 Jun 15;67(12):5889-95
pubmed: 17575158
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
J Natl Cancer Inst. 2014 Jun 28;106(8):
pubmed: 24974129
Cancer Res. 2012 Sep 15;72(18):4840-5
pubmed: 22787119
Int J Cancer. 2001 Jun 1;92(5):641-50
pubmed: 11340566
Genome Med. 2014 Dec 03;6(12):105
pubmed: 25587357
Cancer Res. 2008 Feb 1;68(3):918-26
pubmed: 18245495
Am J Pathol. 2009 Aug;175(2):636-48
pubmed: 19608876
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
J Pathol. 2007 Jul;212(3):316-24
pubmed: 17503414
Semin Cell Dev Biol. 2016 Feb;50:125-32
pubmed: 26791049
PLoS One. 2012;7(2):e31507
pubmed: 22363658
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
PLoS Med. 2010 Jul 13;7(7):e1000307
pubmed: 20644708
J Clin Med. 2017 Jan 05;6(1):
pubmed: 28067794
Curr Oncol Rep. 2013 Apr;15(2):182-9
pubmed: 23341367
Future Oncol. 2005 Dec;1(6):821-8
pubmed: 16556062
PLoS Comput Biol. 2012;8(5):e1002511
pubmed: 22615549
Cell. 2016 Feb 25;164(5):1015-30
pubmed: 26898331

Auteurs

Claire S Reader (CS)

Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Sabari Vallath (S)

Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Colin W Steele (CW)

Cancer Research UK Beatson Institute, Glasgow, UK.

Syed Haider (S)

Institute of Cancer Research, London, UK.

Adam Brentnall (A)

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Ami Desai (A)

Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Kate M Moore (KM)

Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Nigel B Jamieson (NB)

Academic Unit of Surgery, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.

David Chang (D)

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Peter Bailey (P)

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Aldo Scarpa (A)

ARC-NET Research Centre for Applied Research on Cancer, University of Verona, Verona, Italy.

Rita Lawlor (R)

ARC-NET Research Centre for Applied Research on Cancer, University of Verona, Verona, Italy.

Claude Chelala (C)

Centre for Molecular Oncology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Stephen M Keyse (SM)

Division of Cancer Research, University of Dundee, James Arrott Drive, Ninewells Hospital and Medical School, Dundee, UK.

Andrew Biankin (A)

Centre for Molecular Oncology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Jennifer P Morton (JP)

Cancer Research UK Beatson Institute, Glasgow, UK.

Tr Jeffry Evans (TJ)

Cancer Research UK Beatson Institute, Glasgow, UK.
Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Simon T Barry (ST)

Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.

Owen J Sansom (OJ)

Cancer Research UK Beatson Institute, Glasgow, UK.

Hemant M Kocher (HM)

Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

John F Marshall (JF)

Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH